{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:38:54Z","timestamp":1791567534324,"version":"4.3.4"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40266-021-00867-1","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T04:02:31Z","timestamp":1625457751000},"page":"559-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Diagnosis and Management of Pain in Parkinson's Disease: A New Approach"],"prefix":"10.1007","volume":"38","author":[{"given":"Veit","family":"Mylius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Carsten","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bohlhalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ciampi de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-6512","authenticated-orcid":false,"given":"Santiago","family":"Perez Lloret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"issue":"1","key":"867_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.14802\/jmd.20079","volume":"14","author":"M Lubomski","year":"2021","unstructured":"Lubomski M, Davis RL, Sue CM. Health-related quality of life for Parkinson\u2019s disease patients and their caregivers. J Mov Disord. 2021;14(1):42\u201352.","journal-title":"J Mov Disord."},{"issue":"8","key":"867_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrn.2017.91","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(8):509.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"867_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jpainsymman.2006.05.020","volume":"32","author":"MA Lee","year":"2006","unstructured":"Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson\u2019s disease. J Pain Symptom Manage. 2006;32(5):462\u20139.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"867_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/j.pain.0000000000002107","volume":"162","author":"V Mylius","year":"2021","unstructured":"Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, et al. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain. 2021;162(4):1201\u201310.","journal-title":"Pain"},{"issue":"7","key":"867_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000507","volume":"157","author":"E Kosek","year":"2016","unstructured":"Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice AS, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382\u20136.","journal-title":"Pain"},{"issue":"1","key":"867_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","volume":"160","author":"RD Treede","year":"2019","unstructured":"Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1):19\u201327.","journal-title":"Pain"},{"issue":"6","key":"867_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40266-019-00654-z","volume":"36","author":"M Klietz","year":"2019","unstructured":"Klietz M, Greten S, Wegner F, Hoglinger GU. Safety and tolerability of pharmacotherapies for Parkinson\u2019s disease in geriatric patients. Drugs Aging. 2019;36(6):511\u201330.","journal-title":"Drugs Aging"},{"issue":"6","key":"867_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360.","journal-title":"JAMA"},{"issue":"11","key":"867_CR9","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/mds.21105","volume":"21","author":"HL Katzen","year":"2006","unstructured":"Katzen HL, Levin BE, Weiner W. Side and type of motor symptom influence cognition in Parkinson\u2019s disease. Mov Disord. 2006;21(11):1947\u201353.","journal-title":"Mov Disord"},{"issue":"4","key":"867_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3233\/JPD-202088","volume":"10","author":"P Ghosh","year":"2020","unstructured":"Ghosh P, Imbriani P, Caputi N, Natoli S, Schirinzi T, Di Lazzaro G, et al. A dual centre study of pain in Parkinson\u2019s disease and its relationship with other non-motor symptoms. J Parkinsons Dis. 2020;10(4):1817\u201325.","journal-title":"J Parkinsons Dis"},{"issue":"Suppl 1","key":"867_CR11","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","volume":"22","author":"A Sauerbier","year":"2016","unstructured":"Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson\u2019s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S41\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"867_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.parkreldis.2015.01.017","volume":"21","author":"V Low","year":"2015","unstructured":"Low V, Ben-Shlomo Y, Coward E, Fletcher S, Walker R, Clarke CE. Measuring the burden and mortality of hospitalisation in Parkinson\u2019s disease: a cross-sectional analysis of the English Hospital Episodes Statistics database 2009\u20132013. Parkinsonism Relat Disord. 2015;21(5):449\u201354.","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"867_CR13","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson\u2019s disease symptoms: the patient\u2019s perspective. Mov Disord. 2010;25(11):1646\u201351.","journal-title":"Mov Disord"},{"issue":"1","key":"867_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00455-015-9671-9","volume":"31","author":"I Suttrup","year":"2016","unstructured":"Suttrup I, Warnecke T. Dysphagia in Parkinson\u2019s disease. Dysphagia. 2016;31(1):24\u201332.","journal-title":"Dysphagia"},{"issue":"1","key":"867_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-017-0904-4","volume":"17","author":"G McLean","year":"2017","unstructured":"McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson\u2019s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126.","journal-title":"BMC Neurol"},{"key":"867_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fneur.2018.00120","volume":"9","author":"M Klietz","year":"2018","unstructured":"Klietz M, Tulke A, Muschen LH, Paracka L, Schrader C, Dressler DW, et al. Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson\u2019s disease patients. Front Neurol. 2018;9:120.","journal-title":"Front Neurol"},{"issue":"9","key":"867_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archneurol.2008.2","volume":"65","author":"G Defazio","year":"2008","unstructured":"Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65(9):1191\u20134.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"867_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pain.2008.12.004","volume":"141","author":"AG Beiske","year":"2009","unstructured":"Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson\u2019s disease: prevalence and characteristics. Pain. 2009;141(1\u20132):173\u20137.","journal-title":"Pain"},{"key":"867_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41531-017-0009-1","volume":"3","author":"P Martinez-Martin","year":"2017","unstructured":"Martinez-Martin P, Manuel Rojo-Abuin J, Rizos A, Rodriguez-Blazquez C, Trenkwalder C, Perkins L, et al. Distribution and impact on quality of life of the pain modalities assessed by the King\u2019s Parkinson\u2019s disease pain scale. NPJ Parkinsons Dis. 2017;3:8.","journal-title":"NPJ Parkinsons Dis."},{"issue":"36","key":"867_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","volume":"67","author":"J Dahlhamer","year":"2018","unstructured":"Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"867_CR21","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1212\/01.WNL.0000130455.38550.9D","volume":"62","author":"R Djaldetti","year":"2004","unstructured":"Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62(12):2171\u20135.","journal-title":"Neurology"},{"issue":"10","key":"867_CR22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/jnnp.2007.120212","volume":"78","author":"A Gerdelat-Mas","year":"2007","unstructured":"Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, et al. Levodopa raises objective pain threshold in Parkinson\u2019s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78(10):1140\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"867_CR23","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/mds.23825","volume":"26","author":"V Mylius","year":"2011","unstructured":"Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, Moller JC. Pain sensitivity and clinical progression in Parkinson\u2019s disease. Mov Disord. 2011;26(12):2220\u20135.","journal-title":"Mov Disord"},{"issue":"1","key":"867_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1136\/jnnp.2008.145995","volume":"80","author":"V Mylius","year":"2009","unstructured":"Mylius V, Engau I, Teepker M, Stiasny-Kolster K, Schepelmann K, Oertel WH, et al. Pain sensitivity and descending inhibition of pain in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2009;80(1):24\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"867_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.22111","volume":"23","author":"SY Lim","year":"2008","unstructured":"Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson\u2019s disease? Mov Disord. 2008;23(12):1689\u201395.","journal-title":"Mov Disord"},{"issue":"12","key":"867_CR26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/mds.20629","volume":"20","author":"C Brefel-Courbon","year":"2005","unstructured":"Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson\u2019s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20(12):1557\u201363.","journal-title":"Mov Disord"},{"issue":"5","key":"867_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.parkreldis.2013.02.003","volume":"19","author":"C Brefel-Courbon","year":"2013","unstructured":"Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(5):548\u201352.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"867_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00702-019-01974-5","volume":"126","author":"E Dellapina","year":"2019","unstructured":"Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, et al. Dopaminergic denervation using [(123)I]-FPCIT and pain in Parkinson\u2019s disease: a correlation study. J Neural Transm (Vienna). 2019;126(3):279\u201387.","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"867_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00401-007-0193-x","volume":"113","author":"H Braak","year":"2007","unstructured":"Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson\u2019s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113(4):421\u20139.","journal-title":"Acta Neuropathol"},{"issue":"Pt 7","key":"867_CR30","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/brain\/awn102","volume":"131","author":"M Nolano","year":"2008","unstructured":"Nolano M, Provitera V, Estraneo A, Selim MM, Caporaso G, Stancanelli A, et al. Sensory deficit in Parkinson\u2019s disease: evidence of a cutaneous denervation. Brain. 2008;131(Pt 7):1903\u201311.","journal-title":"Brain"},{"issue":"2\u20133","key":"867_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neulet.2008.09.048","volume":"446","author":"V Mylius","year":"2008","unstructured":"Mylius V, Kunz M, Hennighausen E, Lautenbacher S, Schepelmann K. Effects of ageing on spinal motor and autonomic pain responses. Neurosci Lett. 2008;446(2\u20133):129\u201332.","journal-title":"Neurosci Lett"},{"issue":"15","key":"867_CR32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"issue":"1","key":"867_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mds.27862","volume":"35","author":"KR Chaudhuri","year":"2020","unstructured":"Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, et al. The movement disorder society nonmotor rating scale: initial validation study. Mov Disord. 2020;35(1):116\u201333.","journal-title":"Mov Disord"},{"issue":"2","key":"867_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O\u2019Brien CF, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"867_CR35","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901\u201311.","journal-title":"Mov Disord"},{"issue":"7","key":"867_CR36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323.","journal-title":"Mov Disord"},{"key":"867_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2019.04.025","volume":"64","author":"A Marques","year":"2019","unstructured":"Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, et al. How to diagnose parkinsonian central pain? Parkinsonism Relat Disord. 2019;64:50\u20133.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8494","key":"867_CR38","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0140-6736(86)91674-0","volume":"1","author":"NP Quinn","year":"1986","unstructured":"Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson\u2019s disease. Lancet. 1986;1(8494):1366\u20139.","journal-title":"Lancet"},{"issue":"5","key":"867_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrneurol.2012.54","volume":"8","author":"G Wasner","year":"2012","unstructured":"Wasner G, Deuschl G. Pains in Parkinson disease\u2013many syndromes under one umbrella. Nat Rev Neurol. 2012;8(5):284\u201394.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"867_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mdc3.12217","volume":"2","author":"V Mylius","year":"2015","unstructured":"Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, et al. Pain in Parkinson\u2019s disease: current concepts and a new diagnostic algorithm. Mov Disord Clin Pract. 2015;2(4):357\u201364.","journal-title":"Mov Disord Clin Pract."},{"issue":"1\u20132","key":"867_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","volume":"114","author":"D Bouhassira","year":"2005","unstructured":"Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1\u20132):29\u201336.","journal-title":"Pain"},{"issue":"12","key":"867_CR42","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.26270","volume":"30","author":"KR Chaudhuri","year":"2015","unstructured":"Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, et al. King\u2019s Parkinson\u2019s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623\u201331.","journal-title":"Mov Disord"},{"issue":"10","key":"867_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ene.13691","volume":"25","author":"P Martinez-Martin","year":"2018","unstructured":"Martinez-Martin P, Rizos AM, Wetmore J, Antonini A, Odin P, Pal S, et al. First comprehensive tool for screening pain in Parkinson\u2019s disease: the King\u2019s Parkinson\u2019s Disease Pain Questionnaire. Eur J Neurol. 2018;25(10):1255\u201361.","journal-title":"Eur J Neurol"},{"issue":"6","key":"867_CR44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/mdc3.12384","volume":"3","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Ciampide Andrade D, Lyons KE, Rodriguez-Blazquez C, Chaudhuri KR, Deuschl G, et al. Rating scales for pain in Parkinson\u2019s disease: critique and recommendations. Mov Disord Clin Pract. 2016;3(6):527\u201337.","journal-title":"Mov Disord Clin Pract."},{"issue":"3","key":"867_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ejpain.2008.05.001","volume":"13","author":"M Kunz","year":"2009","unstructured":"Kunz M, Mylius V, Scharmann S, Schepelman K, Lautenbacher S. Influence of dementia on multiple components of pain. Eur J Pain. 2009;13(3):317\u201325.","journal-title":"Eur J Pain"},{"issue":"18","key":"867_CR46","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630\u20135.","journal-title":"Neurology"},{"issue":"1\u20132","key":"867_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neurol.2018.09.016","volume":"175","author":"D Bouhassira","year":"2019","unstructured":"Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175(1\u20132):16\u201325.","journal-title":"Rev Neurol (Paris)."},{"key":"867_CR48","unstructured":"Terminology of The International Association for the Study of Pain (IASP). 2021. https:\/\/www.iasp-pain.org\/Education\/Content.aspx?ItemNumber=1698-Nociplasticpain"},{"issue":"6","key":"867_CR49","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1097\/PR9.0000000000000779","volume":"4","author":"KN Sa","year":"2019","unstructured":"Sa KN, Moreira L, Baptista AF, Yeng LT, Teixeira MJ, Galhardoni R, et al. Prevalence of chronic pain in developing countries: systematic review and meta-analysis. Pain Rep. 2019;4(6):e779.","journal-title":"Pain Rep."},{"issue":"1","key":"867_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ana.22021","volume":"68","author":"C Toth","year":"2010","unstructured":"Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;68(1):28\u201336.","journal-title":"Ann Neurol"},{"issue":"2","key":"867_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jpsychores.2011.01.005","volume":"71","author":"A Hinz","year":"2011","unstructured":"Hinz A, Brahler E. Normative values for the hospital anxiety and depression scale (HADS) in the general German population. J Psychosom Res. 2011;71(2):74\u20138.","journal-title":"J Psychosom Res"},{"issue":"4","key":"867_CR52","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"867_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/01.JAM.0000043422.31640.F7","volume":"4","author":"V Warden","year":"2003","unstructured":"Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9\u201315.","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"867_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/JGP.0b013e31818af7ef","volume":"17","author":"U Ehrt","year":"2009","unstructured":"Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry. 2009;17(4):269\u201375.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"867_CR55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398.","journal-title":"Mov Disord"},{"issue":"12","key":"867_CR56","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S1474-4422(15)00243-4","volume":"14","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Valis M, et al. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson\u2019s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14(12):1161\u201370.","journal-title":"Lancet Neurol"},{"issue":"7","key":"867_CR57","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/jcph.678","volume":"56","author":"O Rascol","year":"2016","unstructured":"Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson\u2019s disease-associated chronic pain. J Clin Pharmacol. 2016;56(7):852\u201361.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"867_CR58","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/mds.22546","volume":"24","author":"A Nebe","year":"2009","unstructured":"Nebe A, Ebersbach G. Pain intensity on and off levodopa in patients with Parkinson\u2019s disease. Mov Disord. 2009;24(8):1233\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"867_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pnpbp.2009.09.023","volume":"34","author":"MA Stacy","year":"2010","unstructured":"Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):57\u201361.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"867_CR60","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/ene.12757","volume":"22","author":"A Antonini","year":"2015","unstructured":"Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson\u2019s disease presenting with non-motor symptoms\u2014results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22(10):1400\u20137.","journal-title":"Eur J Neurol"},{"issue":"1","key":"867_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90\u20139.","journal-title":"Mov Disord"},{"issue":"14","key":"867_CR62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2377-14-42","volume":"6","author":"J Kassubek","year":"2014","unstructured":"Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson\u2019s disease: a post hoc analysis of the RECOVER study. BMC Neurol. 2014;6(14):42.","journal-title":"BMC Neurol"},{"issue":"6","key":"867_CR63","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573\u201380.","journal-title":"Lancet Neurol"},{"issue":"10","key":"867_CR64","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","volume":"61","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61(10):1563\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"867_CR65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T Muller","year":"2017","unstructured":"Muller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56(3):251\u201361.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"867_CR66","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29(2):229\u201337.","journal-title":"Mov Disord"},{"issue":"1","key":"867_CR67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3233\/JPD-160911","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of safinamide on pain in fluctuating Parkinson\u2019s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7(1):95\u2013101.","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"867_CR68","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29(10):1273\u201380.","journal-title":"Mov Disord"},{"issue":"4","key":"867_CR69","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","volume":"35","author":"C Cattaneo","year":"2018","unstructured":"Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain. Adv Ther. 2018;35(4):515\u201322.","journal-title":"Adv Ther"},{"issue":"8","key":"867_CR70","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","volume":"127","author":"C Geroin","year":"2020","unstructured":"Geroin C, Di Vico IA, Squintani G, Segatti A, Bovi T, Tinazzi M. Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: an exploratory study. J Neural Transm (Vienna). 2020;127(8):1143\u201352.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"867_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3233\/JPD-202224","volume":"11","author":"G Abbruzzese","year":"2021","unstructured":"Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kagi G, Raw J, et al. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial. J Parkinsons Dis. 2021;11(1):187\u201398.","journal-title":"J Parkinsons Dis"},{"issue":"6","key":"867_CR72","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/WNF.0000000000000051","volume":"37","author":"T Kumagai","year":"2014","unstructured":"Kumagai T, Nagayama H, Ota T, Nishiyama Y, Mishina M, Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2014;37(6):173\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"867_CR73","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.parkreldis.2014.04.007","volume":"20","author":"C Noack","year":"2014","unstructured":"Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(8):815\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1\u20132","key":"867_CR74","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","volume":"319","author":"H Doi","year":"2012","unstructured":"Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson\u2019s disease. J Neurol Sci. 2012;319(1\u20132):86\u20138.","journal-title":"J Neurol Sci"},{"issue":"2","key":"867_CR75","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","volume":"33","author":"J Kulisevsky","year":"2010","unstructured":"Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson\u2019s disease: meta-analysis of randomized controlled trials. Drug Saf. 2010;33(2):147\u201361.","journal-title":"Drug Saf"},{"issue":"Suppl 2","key":"867_CR76","doi-asserted-by":"publisher","first-page":"S309","DOI":"10.1007\/s00415-010-5718-x","volume":"257","author":"JM Miyasaki","year":"2010","unstructured":"Miyasaki JM. Evidence-based initiation of dopaminergic therapy in Parkinson\u2019s disease. J Neurol. 2010;257(Suppl 2):S309\u201313.","journal-title":"J Neurol"},{"issue":"79","key":"867_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejps.2015.09.004","volume":"15","author":"J Knop","year":"2015","unstructured":"Knop J, Hoier E, Ebner T, Fromm MF, Muller F. Renal tubular secretion of pramipexole. Eur J Pharm Sci. 2015;15(79):73\u20138.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"867_CR78","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13318-013-0153-x","volume":"39","author":"W Cawello","year":"2014","unstructured":"Cawello W, Fichtner A, Boekens H, Braun M. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet. 2014;39(3):155\u201363.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"867_CR79","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18\u201327.","journal-title":"Ann Neurol"},{"issue":"4","key":"867_CR80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","volume":"20","author":"D Van Booven","year":"2010","unstructured":"Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20(4):277\u201381.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"867_CR81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, et al. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154\u201365.","journal-title":"Lancet Neurol"},{"issue":"4","key":"867_CR82","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/1871527316666170124165222","volume":"16","author":"L Dezsi","year":"2017","unstructured":"Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425\u201339.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"12","key":"867_CR83","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/phar.1500","volume":"34","author":"M Panisset","year":"2014","unstructured":"Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J, investigators Ss. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34(12):1250\u20138.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"867_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clpt.2004.09.004","volume":"77","author":"M Anttila","year":"2005","unstructured":"Anttila M, Sotaniemi EA, Pelkonen O, Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther. 2005;77(1):54\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"867_CR85","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. 2017;32(12):1701\u20139.","journal-title":"Mov Disord"},{"issue":"3","key":"867_CR86","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF03161197","volume":"4","author":"M Schwartz","year":"2008","unstructured":"Schwartz M, Patel M, Kazzi Z, Morgan B. Cardiotoxicity after massive amantadine overdose. J Med Toxicol. 2008;4(3):173\u20139.","journal-title":"J Med Toxicol"},{"issue":"4","key":"867_CR87","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/wnf.0b013e3180340319","volume":"30","author":"R Djaldetti","year":"2007","unstructured":"Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007;30(4):201\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"867_CR88","doi-asserted-by":"publisher","first-page":"116833","DOI":"10.1016\/j.jns.2020.116833","volume":"414","author":"H Iwaki","year":"2020","unstructured":"Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson\u2019s disease. J Neurol Sci. 2020;414:116833.","journal-title":"J Neurol Sci"},{"issue":"4","key":"867_CR89","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00415-017-8426-y","volume":"264","author":"C Buhmann","year":"2017","unstructured":"Buhmann C, Wrobel N, Grashorn W, Fruendt O, Wesemann K, Diedrich S, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol. 2017;264(4):758\u201369.","journal-title":"J Neurol"},{"key":"867_CR90","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/JPR.S164939","volume":"11","author":"U Freo","year":"2018","unstructured":"Freo U, Furnari M, Ori C. Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson\u2019s disease. J Pain Res. 2018;11:1849\u201356.","journal-title":"J Pain Res"},{"issue":"3","key":"867_CR91","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ejp.942","volume":"21","author":"A Shohet","year":"2017","unstructured":"Shohet A, Khlebtovsky A, Roizen N, Roditi Y, Djaldetti R. Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson\u2019s disease. Eur J Pain. 2017;21(3):486\u201393.","journal-title":"Eur J Pain"},{"issue":"6","key":"867_CR92","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","volume":"40","author":"Y Balash","year":"2017","unstructured":"Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, et al. Medical Cannabis in Parkinson disease: real-life patients\u2019 experience. Clin Neuropharmacol. 2017;40(6):268\u201372.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"867_CR93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","volume":"37","author":"I Lotan","year":"2014","unstructured":"Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014;37(2):41\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"867_CR94","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088\u201398.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"867_CR95","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"CB Carroll","year":"2004","unstructured":"Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245\u201350.","journal-title":"Neurology"},{"issue":"1","key":"867_CR96","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JPD-202260","volume":"11","author":"F Yenilmez","year":"2021","unstructured":"Yenilmez F, Frundt O, Hidding U, Buhmann C. Cannabis in Parkinson\u2019s disease: the patients\u2019 view. J Parkinsons Dis. 2021;11(1):309\u201321.","journal-title":"J Parkinsons Dis"},{"key":"867_CR97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.10.009","volume":"46","author":"I Rieu","year":"2018","unstructured":"Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, et al. Incobotulinum toxin A in Parkinson\u2019s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord. 2018;46:9\u201315.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"867_CR98","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/cjn.2017.245","volume":"45","author":"V Bruno","year":"2018","unstructured":"Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH. Botulinum toxin type A for pain in advanced Parkinson\u2019s disease. Can J Neurol Sci. 2018;45(1):23\u20139.","journal-title":"Can J Neurol Sci"},{"issue":"1\u20132","key":"867_CR99","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1\u20132):109\u201318.","journal-title":"Pain"},{"issue":"12","key":"867_CR100","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1185\/03007995.2011.633502","volume":"27","author":"EP Frakes","year":"2011","unstructured":"Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(12):2361\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"867_CR101","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.cger.2016.06.007","volume":"32","author":"ZA Marcum","year":"2016","unstructured":"Marcum ZA, Duncan NA, Makris UE. Pharmacotherapies in geriatric chronic pain management. Clin Geriatr Med. 2016;32(4):705\u201324.","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"867_CR102","first-page":"57","volume":"66","author":"M Wehling","year":"2016","unstructured":"Wehling M. How to use the FORTA (\u201cFit fOR The Aged\u201d) list to improve pharmacotherapy in the elderly. Drug Res (Stuttg). 2016;66(2):57\u201362.","journal-title":"Drug Res (Stuttg)."},{"key":"867_CR103","unstructured":"Wehling M. Forta\u2014Fit for the Aged. 2021. https:\/\/www.umm.uni-heidelberg.de\/klinische-pharmakologie\/forschung\/forta-projekt\/. Accessed Mar 2021."},{"issue":"1","key":"867_CR104","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00702-020-02276-x","volume":"128","author":"S Greten","year":"2021","unstructured":"Greten S, Muller-Funogea JI, Wegner F, Hoglinger GU, Simon N, Junius-Walker U, et al. Drug safety profiles in geriatric patients with Parkinson\u2019s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna). 2021;128(1):49\u201360.","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"867_CR105","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/mds.27860","volume":"34","author":"P Krack","year":"2019","unstructured":"Krack P, Volkmann J, Tinkhauser G, Deuschl G. Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord. 2019;34(12):1795\u2013810.","journal-title":"Mov Disord"},{"issue":"16","key":"867_CR106","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1212\/WNL.0000000000000887","volume":"83","author":"RG Cury","year":"2014","unstructured":"Cury RG, Galhardoni R, Fonoff ET, Dos Santos Ghilardi MG, Fonoff F, Arnaut D, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson disease. Neurology. 2014;83(16):1403\u20139.","journal-title":"Neurology"},{"issue":"2","key":"867_CR107","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ejp.745","volume":"20","author":"RG Cury","year":"2016","unstructured":"Cury RG, Galhardoni R, Fonoff ET, Perez Lloret S, Dos Santos Ghilardi MG, Barbosa ER, et al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2016;20(2):151\u201365.","journal-title":"Eur J Pain"},{"issue":"12","key":"867_CR108","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1097\/j.pain.0000000000000697","volume":"157","author":"RG Cury","year":"2016","unstructured":"Cury RG, Galhardoni R, Teixeira MJ, Dos Santos Ghilardi MG, Silva V, Myczkowski ML, et al. Subthalamic deep brain stimulation modulates conscious perception of sensory function in Parkinson\u2019s disease. Pain. 2016;157(12):2758\u201365.","journal-title":"Pain"},{"key":"867_CR109","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fneur.2020.00009","volume":"11","author":"RG Cury","year":"2020","unstructured":"Cury RG, Teixeira MJ, Galhardoni R, Silva V, Iglesio R, Franca C, et al. Connectivity patterns of subthalamic stimulation influence pain outcomes in Parkinson\u2019s disease. Front Neurol. 2020;11:9.","journal-title":"Front Neurol"},{"issue":"2","key":"867_CR110","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JPD-161042","volume":"7","author":"AA Othman","year":"2017","unstructured":"Othman AA, Rosebraugh M, Chatamra K, Locke C, Dutta S. Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa-carbidopa. J Parkinsons Dis. 2017;7(2):275\u20138.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"867_CR111","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"key":"867_CR112","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13\u201320.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"867_CR113","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","volume":"21","author":"M Buongiorno","year":"2015","unstructured":"Buongiorno M, Antonelli F, Camara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, et al. Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21(8):871\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"867_CR114","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, investigators Gs, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"867_CR115","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1007\/s00415-020-10356-x","volume":"268","author":"F Morgante","year":"2020","unstructured":"Morgante F, Oppo V, Fabbri M, Olivola E, Sorbera C, De Micco R, et al. Levodopa-carbidopa intrajejunal infusion in Parkinson\u2019s disease: untangling the role of age. J Neurol. 2020;268:1728\u201337.","journal-title":"J Neurol"},{"issue":"7","key":"867_CR116","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/ejp.1400","volume":"23","author":"V Nguy","year":"2019","unstructured":"Nguy V, Barry BK, Moloney N, Hassett LM, Canning CG, Lewis SJG, et al. Exercise-induced hypoalgesia is present in people with Parkinson\u2019s disease: two observational cross-sectional studies. Eur J Pain. 2019;23(7):1329\u201339.","journal-title":"Eur J Pain"},{"key":"867_CR117","doi-asserted-by":"publisher","first-page":"232473","DOI":"10.4061\/2011\/232473","volume":"2011","author":"I Reuter","year":"2011","unstructured":"Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson\u2019s disease. J Aging Res. 2011;2011:232473.","journal-title":"J Aging Res"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00867-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-021-00867-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00867-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T17:00:38Z","timestamp":1699203638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-021-00867-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":117,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00867-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"18 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Veit Mylius consulted for Abbvie, and received research grants from Zambon and Mundipharma. He further received support from Boston Scientific, Licher MT, Abbvie, and Medtronic. Santiago Perez-Lloret received honoraria from IPMDS and consulted for ELEA laboratories and Inmunova Laboratories. Jens Carsten M\u00f6ller, Stephan Bohlhalter, and Daniel Ciampi de Andrade have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"VM drafted the first version, DCDA and SPL drafted parts of the manuscript. JCM and SB corrected and improved the first version. All authors improved the subsequent versions and gave their final consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}}]}}